Characterization of the conformational changes associated with protein function is a central goal of structural biology, as such information can lead to an understanding of how to modify and regulate a protein's activity. These dynamic changes are difficult to capture with most conventional approaches. X-ray crystallography provides a high-resolution static snapshot of a protein, but it is usually unable to reveal structural information in flexible, highly dynamic and functionally important regions. Techniques such as those that use cell-based fluorescence resonance energy transfer (FRET) biosensors 1-3 , site-specific chemical labeling coupled with fluorescent molecules 4-6 , nuclear magnetic resonance (NMR) [7] [8] [9] [10] and electron paramagnetic resonance (EPR) 11, 12 analysis have been used previously to infer conformational changes associated with protein activity. Although these biophysical techniques provide insight into conformational changes of a protein, they require a modified or engineered protein construct. For example, FRET-based conformation change studies of membrane proteins require large fluorescent reporters (e.g., GFP or its variants fused through genetic approaches) that may perturb a protein's structure and function, whereas small-molecule fluorescent, NMR-or EPR-based approaches require engineering a series of single-residue mutants to incorporate active reporter probes.
proteome samples have also been evolving recently [42] [43] [44] . Most of these labeling technologies have been used, however, mainly for the purpose of MS-based quantitative proteomics studies to compare the extents of protein expression or protein posttranscriptional modifications under different biological conditions and not on site-specific conformational change studies. The general principle, advantages and limitations of each of these labeling technologies, including the ones described here, chemical labeling of N-ethylmaleimide (NEM) and succinic anhydride (SA) are summarized in Table 1 .
Challenges in structural analysis of G protein-coupled receptors G protein-coupled receptors (GPCRs), also known as seventransmembrane receptors (7TMRs), constitute the largest family of membrane-associated receptors in the mammalian genome, and they are the targets of nearly half of all clinical drugs on the market [45] [46] [47] . They elicit various distinct physiological outcomes by their response to a diverse array of sensory and chemical stimuli.
Upon ligand binding, they undergo conformational changes, and they can signal not only through the G-protein pathways but also through G protein-independent mechanisms by signaling proteins including β-arrestins 48 , the multifunctional adapter proteins that also regulate receptor desensitization and trafficking [49] [50] [51] . A number of ligands, referred to as 'biased ligands', have been shown to selectively activate only one or a subset of these pathways (G proteins and β-arrestins, among others) 52, 53 . Several lines of evidence have now demonstrated that such ligands with varied efficacies stabilize distinct receptor conformations [54] [55] [56] . An understanding of the structural mechanism(s) of GPCR activation upon binding to different ligands has significant implications in facilitating the design of safer and more efficacious therapeutic agents 53 .
Recent advances in solving high-resolution, 3D X-ray crystallographic snapshots of different ligand-bound GPCRs [57] [58] [59] [60] [61] [62] [63] , including the crystal structure of the β 2 AR in complex with heterotrimeric G proteins 63 , have substantially advanced our 16 O and 18 O. Incorporation at the peptide level understanding in terms of atomic level structural details of these receptors. Despite this progress, GPCRs still face major challenges to structural biology tools such as X-ray crystallography, mainly owing to their intrinsic conformational flexibility and dynamic character. For example, to overcome the flexibility problem and to obtain diffractable crystals, special strategies have been used, including insertion of the T4 lysozyme to replace the highly dynamic third intracellular loop (ICL3) 58, 59, 61 , thermostabilization mutations 62 and cocrystallization with antibodies 57, 61 to stabilize specific ligand-bound receptor conformations 57, 61 .
In fact, the highly dynamic structural organizations, including intracellular loops and C termini of these receptors, remain largely unresolved by X-ray crystallography. Importantly, these structural elements are sites of interactions of activated receptor with effectors (e.g., G-proteins, β-arrestins). Therefore, it is unlikely that X-ray crystallography alone will be able to capture the full complexity and dynamics of GPCRs in which structural flexibility appears to be important to assume different conformations. Hence, complementary approaches that allow the characterization of conformational changes and dynamics of these membrane protein GPCRs will be crucial to unraveling novel insights into their mechanism of activation and signaling.
Development of protein CDSiL-MS strategy
Here we describe the development of a general method (CDSiL-MS) for the examination of site-specific protein conformational changes involving in vitro covalent incorporation of stable-isotope reagents at selective sites, followed by MS-based quantitative analysis. This procedure was used in a model GPCR, the human β 2 AR, to characterize various ligand-specific conformations associated with distinct mechanisms 55 . The method specifically uses stable-isotope-coded forms, incorporating protium atoms (the most common hydrogen isotope; 'light') or deuterium atoms ('heavy') into NEM and SA reagents to selectively label thiol groups of cysteines and primary e-amine groups of lysine side chains, respectively, in a protein or protein complex. NEM (NEM-H 5 or NEM-D 5 ) covalently modifies thiol groups of cysteines via a Michael-type addition reaction at the α, β-unsaturated bond, and such reactions occur optimally in the pH range between 6.5 and 7.5 ( Fig. 1a, top) . However, SA (SA-H 4 or SA-D 4 ) reacts with primary e-amino groups of lysine side chains and the N-terminal α-amino group of proteins, in their nonprotonated forms, via one of its chemically equivalent electrophilic carbonyl carbons (Fig. 1b, (Fig. 1b, bottom) . The corresponding protiated-and deuterated-labeled peptide ion peaks are then clearly distinguished by these mass differences (i.e., 5 Da for NEM and 4 Da for SA) during MS analysis by using high-resolution matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS. The approach involves monitoring the extent of labeling of specific cysteine or lysine residues in proteins, quenching at various time points, proteolytically cleaving and quantitatively analyzing by MALDI-TOF MS. Quantification of the reactivity of residues as a function of time, typically in minutes, is achieved by comparing signal intensity ratios between the experimental (heavy) and corresponding reference (light) labeled fragment ion pairs. In general, the advantage of such site-specific stable-isotope chemical labeling techniques is their use in MS-based quantitative proteomics to allow characterization of conformational changes of a wide spectrum of proteins and protein complexes both in vitro with purified proteins and in cell systems. A brief overview of the CDSiL-MS approach, materials required, step-by-step procedures and troubleshooting guidelines are provided below.
Experimental design Procedure overview. An overview of the experimental workflow of protein CDSiL-MS process is shown in Figure 2 . The strategy has four main steps: (i) the reference labeling reaction; (ii) an experimental time point labeling reaction; (iii) sample processing (reduction, alkylation and proteolytic digestion) and MS analysis; and (iv) quantification of site-specific labeling and kinetic analysis.
Differential labeling and MS analysis. The CDSiL-MS approach can technically be applied to different soluble and membrane proteins. We described it here by using a model GPCR: an integral membrane protein, β 2 AR. To shed light on the mechanism of activation of GPCRs from the perspective of ligand-specific conformational rearrangements, we performed CDSiL-MS experiments on β 2 AR in complex with three distinct β-adrenoceptor ligands (test ligands) with different pharmacological properties: the full agonist isoproterenol, the inverse agonist ICI-118,551 (ICI) and a biased ligand carvedilol (carv; a β-antagonist for G protein activation with selective stimulation of β-arrestinmediated signaling 64 ). Before experiments, it is important to confirm the activity of the protein being analyzed by performing functional assays 55, 65 . In this regard, after its expression in Spodoptera frugiperda (Sf9) cells by using the baculovirus system, and after purification by affinity chromatographic steps, β 2 AR activity is confirmed by using radio-ligand binding assays 55, 65 . When performing labeling reactions, high molar excesses of these test ligands are required relative to the receptor, which is typically present at low micromolar concentrations (~2.5 µM).
The saturating ligand concentration guarantees locking the receptor to the specific functional conformation that the ligand prefers, thus allowing homogeneous receptor:ligand complex sample preparations that are suitable for stable-isotope labeling and MS-based quantitative analysis. Obtaining optimal signal intensity of labeled peptide is also an important factor for reproducible quantification. Therefore, it is advisable to first perform experiments to determine the relative reactivity condition of each residue to its respective stable-isotope-labeled reagent. Such pilot experiments can also be designed to include information in identifying the time scale of the labeling reaction for different residues and distribution between time points for the protein in study (Box 1). Along similar lines, choice of proteolytic enzymes for digestion of the protein of interest is also important, as it directly ensures accurate quantification of peptides. Therefore, it is important to initially test a group of proteases so as to select appropriate proteases for accurate quantification of the peptide of interest by MS. In the current study, we used chymotrypsin (which cleaves C-terminally at tryptophan, tyrosine, phenylalanine and leucine residues) to cleave NEM-or SA-labeled protein samples. However, trypsin (cleaves C-terminally at lysine and arginine) is only suitable to cleave NEM-labeled samples, as it partially cleaves SA-labeled ones (only those after arginine).
To perform differential stable-isotope chemical labeling (light/heavy) and to precisely measure the changes in labeling of reactive residues as a function of time, an accurately measured receptor/protein amount to be labeled is prepared. This protein 
Box 1 | Pilot experiments for time point selection
The following steps describe the pilot experiment for the determination of numbers of and distribution between time points for the protein in study. sample is then split into two equal parts that will serve as the reference (Ref reaction) and experimental time-point labeling reaction (Exp reaction). The labeling experiments are designed in a form that the protiated-labeling reagent (NEM-H 5 or SA-H 4 ) is used for the Ref reaction and the deuterated-labeling reagent (NEM-D 5 or SA-D4) is used for the Exp reaction, although technically it can also be designed vice versa. In the first step of the CDSiL-MS approach, the Ref reaction is allowed to take place and is quenched at a fixed time point (typically the time point of the Exp reaction at which the labeling reaction has completed is chosen) and snap-frozen in liquid N 2 (Fig. 2a) . The Exp reaction is allowed to take place under identical conditions except with aliquots removed at different time points, followed by quenching and snap-freezing of each aliquot (Fig. 2b) . Typically, DTT and free l-lysine are used to quench the NEM-and SA-labeling reactions, respectively. Each of the above reactions can be done in parallel or separately depending on the sample sizes, and they can be stored at −80 °C until further use. After completion of labeling, equal aliquots from the Ref and Exp reactions are mixed, precipitated by chloroform/methanol 66 and subjected to in-solution enzymatic digestion with suitable proteases; here chymotrypsin is used. The resulting peptide digests are desalted on reversed-phase C18 adsorbent micro-column and analyzed by MALDI-TOF MS (Fig. 2c) . Spectral acquisition on MALDI-TOF MS is normally set over a 700-4,000 mass-to-charge ratio range (m/z) to analyze suitably sized, reproducible proteolytic peptide fragments away from the matrix interference range (i.e., below 700 m/z).
Quantification is achieved by comparing ion peak signal intensities within the differentially stable isotope-labeled peptide pairs (i.e., the light/heavy peak pairs or 'doublets') at the initial MS level. As the mass differences between labeled peptides are 5 and 4 Da, the overlap between isotopic clusters of light-and heavy-labeled peptide peaks is usually negligible. However, even with similar labeling reagents that allow large mass differences, overlapping of isotopic clusters may occur for labeled peptides larger than 3,000 m/z; in this case, depending on the significance and quality of ion signals, peak signal correction may be required. This in turn is dependent on the sequence coverage of the protein of interest and the proteolytic enzymes used. Therefore, stringent thresholds need to be applied, such as a signal-to-noise ratio greater than 5 and a lack of interfering signals around the peptide of interest. In this regard, performing control inverse labeling experiments (i.e., swapped labeling in which the Exp reaction uses the light isotope and the Ref reaction uses the heavy isotope in the scheme shown in Fig. 2a,b) is recommended in order to quickly identify irrelevant signals and to focus on the signals of interest. Optimal signal ion intensity (i.e., high abundance and signal-to-noise ratio) of labeled peptide ion pairs under study obtained by the MS platform of choice is also important for a reproducible and accurate quantification. As we describe below, to ensure the peptide quantification performance of the MS platform used over a wide dynamic range, the linearity of the response is estimated by comparing the measured peptide ion pair peak intensity ratios with the known amount of the stable-isotopelabeled peptide added in the experiment 55 . Such labeling experiments, which validate the technical reproducibility and accuracy of peptide quantification of the MS platform, can also be performed in both conventional and inverse stable-isotope chemical labeling strategies.
Generation of site-specific labeling profiles. The reactivity of each site in the different receptor:ligand complexes is obtained by measuring the relative signal intensity ratios of the monoisotopic peaks of the deuterated (heavy) to the protiated (light) reagentmodified peptides to yield the percentage intensity ratio, %R(t), for each time point and site. The calculated curves in the form of percentage intensity ratios (%R(t)) can then be directly fit with a suitable exponential kinetic model (equations 2-4) or they can be normalized (Fig. 2d) . Normalization of percentage intensity ratios allows a comparison of reactivities between different residues within a given protein. A normalization factor, termed the reactivity factor, R r , can be determined experimentally, and it relates %R(t) to the percentage of the site labeled, %F(t):
where %F(t) is the fraction of the site labeled, %R(t) is the ratio of the heavy-to-light signal intensity for time point t and R r is the reactivity factor. An alternative approach to bypass any normalization of initial percentage signal intensity (%R) data is to use a synthetic stable-isotope-labeled internal standard of identical sequence to replace the Ref reaction in the experimental scheme shown in Figure 2a . The relative reactivity of a given amino acid residue can then be determined from the ion abundance ratio between the standard and the experimental version of the modified peptide (i.e., light and heavy) at each labeling reaction time point. Hence, the resulting percentage intensity ratios (%R) are plotted as a function of time to obtain time-course labeling curves for kinetic analysis. Conceptually, the application of a stable-isotope-labeled internal standard in CDSiL-MS is similar to that used by the method of absolute quantification (AQUA), which requires internal peptide standard for the quantification of levels of post-translational modifications of proteins in complex biological samples 67, 68 .
Methods of analysis of labeling data.
In general, the model used to fit the data should be the simplest possible model that provides a similar goodness of fit as assessed statistically, e.g., by R 2 values. To determine the appropriate fitting model, the reactivity data (in the form of %R or %F) as a function of time in minutes are plotted. These curves (e.g., each site/ligand pair) are tested for their best fit to different exponential models (Fig. 3) . If the labeling of a given site in a protein occurs through a simple kinetic mechanism, the labeling data can be fit by simple exponential kinetics behavior. It is likely, however, that some labeling may occur very rapidly in a burst phase, before the first time point of the experiment (Fig. 3a) . A simple curve that fits such behavior is
where t is the labeling time; τ 1 is the relaxation time constant; A is the amplitude response of the phase; and (100−A) is the burst-phase amplitude.
If there is no burst phase, but rather two relaxations that occur over the time scale of the experiment (Fig. 3b) , the data can be fit to where τ 1 and τ 2 are the relaxation time constants of each phase, and A is the fractional amplitude of the τ 1 phase. If a burst phase is present in the data, as well as two other relaxations (Fig. 3c) , the data can be fit to (4) where A and B are the amplitudes of the phases with relaxation times τ 1 and τ 2 , respectively, and the burst phase amplitude is (100 − A − B). In all three models, force F(∞) = 100, which is expected from the experimental design. Such curve fitting allows a quantitative comparison of the labeling kinetics at different sites in a given conformation of a protein. Moreover, these relaxations are related to the different underlying conformational states and their interconversions, and they define the minimum number of conformational states in the system. In our experience, we have found that relaxation times are the most informative of the kinetic parameters that are used for interpretation and comparison of the labeling kinetics of different amino acid residues on various conformations of a protein. The relaxation times are transformed to a labeling reactivity factor (L-factor), which is equal to the negative logarithm of the relaxation time (−log τ 1 ). The L factor is defined as (−log τ 1 ), so it is proportional to the activation energy associated with residue labeling.
Reactivity measurements are sensitive to the conformational state of the receptor/protein, and thus changes in L-factor reflect ligand-dependent conformational rearrangements in the vicinity of the site (residues that are labeled relatively quickly would have high L-factors, and vice versa). The relative reactivity of a given amino acid side chain in a protein with its respective stableisotope reagent upon conformational changes is also a function of the pKa and the protonation state of the residue, which can be modified by changes in the residue's microenvironment within the protein 3D structure. Thus, it should be kept in mind that a change in a residue's labeling factor could be due to a number of different changes in the protein 
Determination of the linearity range of labeling experiment.
The accuracy and sensitivity of peptide quantification over a wide dynamic range is confirmed by performing dilution curves over a series of mixtures of light-:heavy-labeled peptides. This experiment is prepared in two separate stable-isotope-labeling reaction pools of β 2 AR (2.5 µM), one with NEM-H 5 (2 mM) and the other with NEM-D 5 (2 mM), each incubated for 1 h at room temperature (20-25 °C) and quenched. The NEM-D 5 -labeled samples are spiked into NEM-H 5 -labeled reference samples in seven different dilutions as a dilution series (twofold concentration dilutions ranging from 1:1 to 1:128), and then they are concurrently digested and analyzed by MS. Quantitative comparison between measured peptide intensity ratios (NEM-H 5 /NEM-D 5 ) and dilution series of expected ratios (1:1 to 1:128) of labeled β 2 AR allows the determination of the linearity range of measurements of isotopically labeled peptide using the MS instrument. To ensure reliability of the data, we also performed this experiment in an inverse labeling mode (i.e., label swap where NEM-H 5 -labeled samples are spiked into NEM-D 5 -labeled samples). A typical example is illustrated with the quantification of one of the longest peptide isotope peak pairs ( 327 CRSPDFRIAF 336 modified at Cys327 by NEM-H 5 or NEM-D 5 ) shown in Figure 4a ,b. We observed a strong linear relationship between signal intensities and molar concentration ratios of the labeled protein (slope = 0.9785 ± 0.13; R 2 = 0.9996; P < 0.0001). Figure 4c illustrates the linearity of response observed in this experimental design (i.e., good correlation between intensities and absolute concentrations). Thus, we find that the MALDI-TOF MS analytical platform used here is robust and quantitative with a linear dynamic range of over two orders of magnitude.
In addition to the robust nature of its protein quantification, MALDI-TOF MS has other practical features, including its ability to (i) rapidly analyze a large number of samples in a short period of time, allowing for automation and high-throughput formatting; (ii) generate singly charged precursor ions, which simplifies ion selection from MS spectra; (iii) prevent potential uncertainties that could otherwise occur during chromatographic separation of the deuterated-and protiated-labeled peptide pairs when using LC-MS analysis; (iv) be compatible with sample storage and reanalysis; and (v) provide high-quality data when working with purified proteins and protein complexes formed in vitro.
Limitations of this approach. There are potential limitations to the CDSiL-MS approach. For example, the protein of interest may have cysteine or lysine residues that are crucial for its activity. Similarly, the protein may have labile disulfide bonds (as Cys residues are assumed to be unreactive in disulfide form) that are important for its structural integrity. In such instances, reactions with NEM or SA would inactivate or structurally compromise the protein. Alternative approaches such as hydrogen/deuterium exchange coupled with MS (HDX/MS) 21, 24 can provide regionspecific functional conformational dynamics of proteins in such cases. In addition, although one of the advantages of CDSiL-MS is its ability to simultaneously detect reactivities of multiple residues from different locations of a native protein, some proteins may lack native-reactive cysteines or lysines at desirable conformationsensitive regions. In such instances, applications of CDSiL-MS would therefore require the generation of mutant proteins, which is more labor intensive. Finally, when studying dynamics and structural mapping of protein complexes with any covalent stable-isotope labeling such as CDSiL-MS, it can be difficult to discern whether changes in labeling are a result of intra-or intermolecular conformational changes. Again, in such circumstances, complementary approaches may be required. 
MaterIals

REAGENTS
REAGENT SETUP Protein expression and purification Depending on the protein of interest, the expression system and purification strategy may vary. For purification of the human β 2 AR, we typically express it in baculovirus-infected Sf9 insect cells as N-terminal FLAG-tagged and C-terminal hexahistidine-tagged protein and subsequently purify it after solubilizing it in DDM detergent by using three-step affinity-chromatographic procedures as described previously 65 . Purity and activity of the purified protein is assessed by Coomassie blue staining resolved on SDS-PAGE and radio-ligand binding assays, respectively. equipped with a nitrogen laser operating at 337 nm, a video system and 4000-series Data Explorer software for spectra acquisition and instrument control. Peptide samples (0.4 µl) are spotted onto the MALDI target plate, followed by the addition of an equal volume of the matrix solution; the mixture is allowed to co-crystallize at room temperature. All mass spectra can be obtained in the reflection positive-ion mode at an acceleration voltage of 20 kV and a detector voltage of 2 kV. MS data can be automatically acquired over the range of 700-4,000 m/z; laser intensity can be adjusted to obtain optimized resolution.
proceDure protein sample preparation and receptor-ligand binding 1| Dialyze the protein solution against 50 mM potassium phosphate buffer (pH 7.5), containing 100 mM NaCl and 0.02% (wt/vol) DDM. Perform three buffer changes twice every hour, and do the last one overnight.  crItIcal step It is important to avoid buffers that contain primary amines, such as Tris, because these will compete for conjugation with the amine-reactive reagent such as SA and affect labeling efficiency. ? troublesHootInG 2| Add glycerol to a concentration of 15% (vol/vol) and dispense the protein sample into single-use aliquots in 1.5-ml centrifuge tubes. Each tube should contain an accurately measured protein amount of 65 µg, which is sufficient to perform a single experimental condition stable-isotope labeling (i.e., one sample with light isotope and the other with heavy isotope). These protein samples are then stored at −80 °C until needed for 1 year.
? troublesHootInG  pause poInt Aliquots of protein samples can be stored at −80 °C for 1 year.
3|
Adjust the protein concentration to 2.5-5.0 µM with 50 mM potassium phosphate buffer (pH 7.5), containing 100 mM NaCl and 0.02% (wt/vol) DDM. Approximately 65 µg of protein in a 250-µl final volume is required per condition (i.e., receptor/ ligand) to perform a single differential stable-isotope labeling experiment with both light and heavy chemical reagents.  crItIcal step Labeling experiments are performed at least in triplicate to ensure reliability in measurements. Each labeling condition requires about 65 µg of protein, so performing the experiment in triplicate would require ~200 µg. Avoid combining different batches of proteins; use a single batch of validated and dialyzed receptor protein for a given set of experimental conditions (the example in this study for three receptor:ligand pairs and receptor alone, plus validation experiments, would require a total of ~1 mg of protein).
4|
To the 250-µl diluted protein solution in a 1.5-ml microcentrifuge tube, add a test ligand or control (50-100 µM; 10-100-fold molar excess or equivalent amount of carrier solvent for control) and incubate it for 30 min at room temperature. ? troublesHootInG 5| After incubation, the protein/ligand solution is then distributed into two 1.5-ml microcentrifuge tubes in a volume of 120 µl. (Fig. 2) . Use 20 mM DTT in NH 4 It is important that pipetting be as precise as possible to ensure equal mixing of protiated-and deuterated-labeled samples in the next step.
7|
Remove the labeled reaction samples from frozen storage, spin them down quickly for 10 s and mix equal aliquots from the Ref reaction and the Exp reaction in fresh 1.5-ml protein LoBind microcentrifuge tubes to obtain ~20 µl of final mixed volume of the light and heavy labeled samples. Flash-freeze the samples in liquid nitrogen and store them at −80 °C indefinitely without freezing and thawing.  crItIcal step 1.5-ml Protein LoBind microcentrifuge tubes should be used for mixing. ? troublesHootInG  pause poInt At this point, one can continue with Step 8 immediately or pause at this point, leaving samples stored at −80 °C for several weeks. 10| Add 1 volume of CHCl 3 , mix the layers and vortex the mixture for 30 s.
11| Add 3 volumes of double-distilled H 2 O and mix the layers vigorously by vortexing for 30 s.
12| Centrifuge the sample mixture at 12,000g at room temperature in a benchtop microcentrifuge for 2 min.
13|
Carefully remove the aqueous top layer.
 crItIcal step Be sure to mix and vortex the sample before centrifugation to reach the equilibrium of extraction. By using gel-loading tips, carefully remove the top phase without touching the finer emulsion that is created between the aqueous and chloroform layers, which contains the protein of interest.
14| Add 4 volumes of methanol to the tube and vortex the mixture for 30 s.
15| Centrifuge the sample mixture at 12,000g at room temperature in a benchtop microcentrifuge for 5 min.
16|
Carefully remove the methanol without disturbing the solution, as the pellet may be difficult to see, and then vacuum-concentrate (with a SpeedVac or similar) the precipitate for 5 min.  crItIcal step Do not dry the stage-tip column during the column cleaning, wetting, equilibrating, peptide binding and column washing steps. (c) Ziptip c18 desalting  crItIcal step The ZipTip desalting is done essentially according to the manufacturer's protocol with slight modifications. Use a P10 or P20 pipetter set to 10 µl for ZipTips. The resin bed of ZipTip C18 provides back-pressure, so set the pipetter to 10 µl, depress the plunger to dead stop and slowly release or dispense the plunger throughout the operation.  crItIcal step Do not dry the Zip-tip column during the column cleaning, activation, equilibrating, peptide binding and column washing steps.  pause poInt For MALDI-TOF MS analysis, it is highly recommended to proceed to spot samples on plates immediately after elution; otherwise, the samples can be stored at −20 °C for several weeks.
MalDI-toF/toF-Ms and data analysis 25|
Prepare the matrix solution: prepare a saturated solution of α-cyano-4-hydroxycinnamic acid in 20 mM ammonium phosphate, 50% (vol/vol) ACN and 0.2% (vol/vol) TFA, and use it as an ionization matrix.
26|
Spot 0.4 µl of the peptide sample onto a MALDI target plate in triplicate, followed by the addition of an equal volume of the supernatant matrix solution.
27|
Allow the mixture to cocrystallize 70 at room temperature.
28|
Load the MALDI-TOF/TOF target plate into a MALDI-TOF/TOF mass spectrometer.
29|
Acquire spectra, by using a MALDI-TOF/TOF mass spectrometer, over the range of 700-4,000 m/z. See Equipment Setup for details about configuration and settings.  crItIcal step It is important to set spectral acquisition over a mass range of 700-4,000 m/z to analyze suitably sized proteolytic peptides. Analyses of very short peptides that fall below 700 m/z are unreliable because of matrix interferences.
? troublesHootInG 30| Perform spectral data analysis. In our laboratory, mass spectra data analyses are performed with Data Explorer software (version 4.3.0.0, Applied Biosystems). To confirm mass accuracy and to identify uniquely labeled peptides, we preliminarily depend on the appearance of protiated (light) and deuterated (heavy) pairs of peptides that give a mass shift of 5 Da (for NEM labeling) or 4 Da (for SA labeling).
31|
Perform calibration of mass spectra with known mass of proteolytic autolysis fragments (typically using peaks at 705.48 m/z for chymotrypsin or at 842.51 m/z for trypsin, for example) and extract the mass list of monoisotopic peptide peaks.
32| Perform a database search by using Applied Biosystems GPS Explorer software or perform peptide mass fingerprinting analysis by using the Protein Prospector database search algorithm mass list of peptides (http://prospector.ucsf.edu, University of California, San Francisco) in the mass range of 700-4,000 Da. When using this or similar software, adjust search parameters to allow for a maximum of two missed cleavages and a mass tolerance of 50 p.p.m. For identification of NEM-modified peptides, either oxidation of methionines, NEM alkylation or carbamidomethylation of cysteines can be used as variable modifications. For identification of SA-modified peptides, oxidation of methionines, as well as succinylation and carbamylation of lysines, can be used as variable modifications, whereas carbamidomethylation of cysteines can be used as a constant modification.
33|
In addition, to confirm sites of modification by the specific modifying reagents, MS/MS amino acid perform sequence analyses of all the differentially labeled peptides. The resulting spectra can be interpreted manually with the help of the MS-PRODUCT program in Protein Prospector or other available software packages.
34| After calibration, extract data lists of monoisotopic peptide peak mass and intensity from baseline-corrected spectra.  pause poInt At this point, data can be stored and analyzed later.
Quantification of site-specific labeling kinetics 35| Perform quantification at the MS level and measure the relative signal intensity ratios of the monoisotopic peaks of the deuterated (heavy) to protiated (light) reagent-modified peptides to obtain percentage intensity ratios (%R) for each time point and amino acid residue in the protein. Such data analysis can be performed manually by using Data Explorer or other compatible automated software packages that are used for very large numbers of data sets. Monoisotopic peaks should be used for the measurement. As the mass differences between labeled peptides are 5 and 4 Da, the overlap between isotope envelopes of the differentially labeled peptides is usually negligible for most of the peptides. However, for peptides that are bigger than 3,000 m/z, a substantial overlap between isotope envelopes may occur; in this case, depending on the significance and quality of the data, the peak signal intensity ratios can be corrected for by performing further kinetic analysis or they can be totally excluded. The percentage of overlap between isotope envelopes can be calculated by using the program available at http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msisotope.
36|
Plot percentage intensity ratios, denoted as %R (for the ratio between peak intensities of the heavy and light peptides), as a function of time for every labeled residue in a protein to generate time-course labeling curves. In our experience, we find it convenient to plot these data as a semilogarithmic graph where time is on the log scale.
37|
Fit the labeling curves of each site to exponential equations (2-4), starting with a single exponential (equation 2) to determine the appropriate fitting model. The model used to fit the data should be the simplest possible model that provides a similar goodness of fit as assessed statistically (e.g., by R 2 values).
38| Tabulate all the kinetic parameters calculated from the fits (amplitudes of the phases and relaxation times).
39|
We find that the use of relaxation times best interprets the labeling kinetics at different sites. Transform the fast-phase relaxation time to negative logarithmic value (−log τ 1 ) to obtain what we refer to as labeling reactivity factor (L-factor).
Note that, although it may vary from protein to protein, most of our labeling curves were sufficiently described by a double exponential function.
40|
For a given site, compare the L-factor values obtained when the receptor/protein is in its unliganded state and ligand-bound state. Compute the difference between each of these L-factors. Note that reactivity measurements are sensitive to the conformational state of the receptor/protein, and thus change in L-factor computed would reflect ligand-dependent conformational rearrangements in the vicinity of the site (i.e., a large L-factor reflects higher reactivity relative to unliganded receptor/protein-only, and vice versa).
41| Alternatively, the percentage intensity ratios (%R(t)) for each site can also be normalized according to equation 1 by using the term reactivity factor (R r ), which is a normalization factor determined experimentally (Step 57).  crItIcal step Note that normalization of percentage intensity ratios is important to compare reactivities between different residues within a given protein. An alternative approach to normalization is to use a synthetic stable isotope-labeled internal standard of identical sequence to replace the Ref reaction in the experimental scheme shown in Figure 2 .
(optional) estimating the fraction of individual sites labeled at reaction completion  crItIcal The purpose of limited proteolysis of the receptor in the detergent environment is to partially denature the protein and to make cysteine or lysine residues fully available to labeling reagents (NEM or SA). However, care must be taken in designing such experiments with SA labeling at lysines, as full proteolytic cleavage followed by labeling can cause further mass shift because of labeling of the neo-N-terminal amine group.  crItIcal Estimate the fraction of the individual site labeled at the longest time point chosen for the labeling experiment. Although this experiment is optional, it allows a normalization of percentage intensity ratios (%R(t)) to compare the reactivity between different residues. 42| Native protein preparation labeling. Prepare the protein of interest in native conditions, as described in Steps 1 and 2. 
55|
Reconstitute peptide mixtures in 40 µl of 0.3% (vol/vol)TFA, adjust the pH to below 2 and perform peptide desalting by using pipette tips containing C18 medium.
56|
Perform MALDI-TOF MS analysis of spotted samples.
57|
Measure the peak intensities and quantify the ratios of the light-to-heavy reagent-modified peptides for each site to obtain reactivity ratio (R r ).
58|
Use the reactivity ratio (R r ) obtained from Step 57 to normalize the percentage intensity ratios (%R(t)) described in
Step 36, by applying equation 1 to obtain the fraction of sites labeled ((%F(t)).
59|
Plot the percentage reactivity ratios (%F) versus time to establish new labeling curves and to fit each time-dependent labeling profile to an appropriate exponential kinetic equation (equations 2-4).
60|
Repeat Steps 37-39 to compute L-factor values for individual time-dependent labeling profiles.
61|
Statistical significance of the differences between pairs of treatments can be assessed by using one-way ANOVA followed by Bonferroni's post-test, or a Student's two-tailed paired t test, as appropriate, by using Prism 5.01 (GraphPad Software) or an equivalent software package.
? troublesHootInG Troubleshooting advice can be found in table 2.
• tIMInG 
antIcIpateD results
The CDSiL-MS strategy presented here is a versatile technique that can be applied to different soluble and membrane proteins for elucidating conformational rearrangements at a site-specific resolution. We have recently applied the CDSiL-MS methodology to study the dynamics of various ligand-occupied structural conformations of the human β 2 AR, which is a well-studied GPCR 55 . An initial requirement for the method is to characterize the functional and ligand-binding properties of the protein of interest to ensure that its structural integrity is preserved during labeling experiments. In addition, the method also relies on obtaining optimal signal ion intensity (i.e., high abundance and signal-to-noise ratio) of the labeled peptide ion pairs under study for accurate quantification. As determined by linear response experiment, a typical labeled peptide ion pair shows a strong linear relationship between measured peptide ion pair peak intensity ratios and applied dilution of labeled protein concentrations (slope = 0.9785 ± 0.13; R 2 = 0.9996; P < 0.0001) (Fig. 4) .
To illustrate the procedures of the CDSiL-MS strategy, we show the results on two residues located in conformationsensitive regions of β 2 AR (Fig. 5a ): Cys 327, located in the intracellular portion of transmembrane helix 7 (TM7) near the NPxxY motif, and Lys 263, located in the third intracellular loop (ICL3) at the cytoplasmic end of TM6, where larger conformational change occurs during receptor activation and G protein binding 61, 63 . We use three functionally distinct ligands consisting of an agonist isoproterenol (iso), an inverse agonist ICI-118,551 (ICI) and a biased ligand carvedilol (carv; a β-antagonist for G protein activation with selective stimulation of β-arrestin-mediated signaling 64 ). The labeling of the Cys 327 residue by NEM is identified by singly charged ion ([M + H] + ) peaks ( 327 CRSPDFRIAF 336 ) at m/z 1,336.6 and 1,341.7 (Fig. 5b) . However, the labeling of Lys 263 residue by SA is identified by singly charged ion ([M + H] + ) peaks ( 259 RRSSKF 264 ) at m/z 880.5 and 884.5 corresponding to peptide modification by SA-H 4 and SA-D 4 , respectively (Fig. 5c) . Figure 6 shows plots of percentage intensity ratios (%R(t)), i.e., the ratios of intensities of monoisotopic peaks of the deuterated (heavy) to protiated (light) NEM or SA-labeled peptides as a function of time, respectively. Such time-course labeling curves in the form of percentage intensity ratios (%R(t)) can be used directly to fit with a suitable exponential kinetic model (equations 2-4) or they can be normalized. It is important to normalize %R(t) to % F(t) by using reactivity factor (R r ) via equation 1 when comparison in the reactivities between different residues within a given protein is desired. form of %F(t) by using equation 1 (Fig. 6b,e) . These labeling data (%F(t)) are well described by double exponentials (equation 3) with fast and slow relaxation times, and they produce excellent fits to the data with R 2 values greater than 0.994. The fast-phase relaxation times (τ 1 ) in min at Cys 327 were 3.87 ± 0.1 (none), 1.89 ± 0.2 (iso), 5.32 ± 0.6 (ICI) and 5.32 ± 0.5 (carv), whereas at Lys 263 the values were 0.68 ± 0.1 (none), 0.50 ± 0.1 (iso), 0.59 ± 0.1 (ICI) and 0.22 ± 0.1 (carv).
To quantitatively compare the labeling kinetics of the residues and associated conformational rearrangement upon ligand binding, the fast relaxation times are transformed to negative logarithmic value (−log τ 1 ) to obtain labeling reactivity factor (L-factor) (Fig. 6c,f) . Reactivity measurements are sensitive to the conformational state of a protein, and thus a change in L-factor computed would reflect ligand-dependent conformational rearrangements in the vicinity of the site (a large L-factor reflects higher reactivity relative to unliganded protein, and vice versa). As illustrated in Figure 6c , the full agonist (isoproterenol)-bound β 2 AR induces the highest reactivity (L-factor) at Cys 327 compared with others (P < 0.01, iso versus none or ICI, one-way ANOVA), suggesting structural rearrangements upon agonist binding and receptor activation 55, 61, 63 . These results are in agreement with the observations of large conformational rearrangements at the cytosolic end of TM7 (where Cys 327 is located) in the activated form of the β 2 AR in the X-ray crystal structures 61, 63 and from a conformational dynamics study by HDX/MS 23 . Similarly, at Lys 263, a markedly higher L-factor in the carvedilol-bound β 2 AR complex is observed relative to that of the pharmacologically similar ligand, ICI, for G-protein inactivation or unliganded-β 2 AR (P < 0.05, carv versus none) (Fig. 6f) , which is consistent with ligand-specific structural rearrangements at these regions of the receptor.
We have demonstrated the method here by using a pair of residues; similar reactivity measurements can be done to demonstrate it in a time-dependent manner upon binding to different ligands, for several other residues located in different regions of the receptor 55 (Fig. 7a) , including the ones that are absent in the X-ray crystal structures, obtained from engineered protein-GPCR constructs (Fig. 7b) . Taken together, the data suggest that the ability of functionally different ligands to alter local conformational rearrangements (intracellular or extracellular regions) indicates the presence of multiple ligand-specific functional conformations, which may have a role in biased agonism or functional selectivity. The ability of functionally selective ligands to stabilize unique functional conformations was also recently demonstrated by NMR and HDX/MS experiments 9, 10, 23, 71 . This highlights the complementary nature of different structural biology methods in providing a comprehensive understanding of conformational changes associated with a protein's function.
In conclusion, the CDSiL-MS strategy described here provides a reliable and cost-effective way to monitor and precisely measure site-specific conformational dynamics of proteins via stable-isotope labeling coupled with MS-based quantitative analysis. As MS instrumentation and methods of quantitative stable-isotope covalent labeling strategies continue to evolve, it is anticipated that the protocol presented here will also improve quickly for broad-range proteome applications. In the near future, we believe that the approach can be applicable to moderate-or high-throughput systems in which protein targets that undergo function-dependent conformational changes can be interrogated structurally to allow drug screening. and Lys (blue) residues for which reactivities can be monitored. In b, the Cys and Lys residues shown in sphere format are the ones that are available in the X-ray crystal structure. Dashed lines indicate highly flexible regions of the receptor, which are absent in the X-ray crystal structure.
